**Expression of Interest for Collaborative Research Funding**

**For collaborations between**

**AUSTRALIAN MEDICAL RESEARCHERS AND CLINICIANS**

**and**

**ISRAELI MEDICAL RESEARCHERS AND CLINICIANS**

|  |
| --- |
| Expression of Interest for Research Funding  Guidelines, and Conditions |
| 1. AUSiMED – Australia Israel Medical Research – is a not-for-profit organisation that facilitates and financially supports collaborations between medical researchers in Israel and Australia. 2. Projects can be new or ongoing and will be accepted for any areas of medical research and development including biopharmaceuticals, new methods of clinical treatment, diagnostics and devices. Only projects focused on clinical outcomes will be considered. 3. This Expression of Interest should provide a brief summary of the collaborative opportunity. 4. The application should be typed in 10 pt Arial font, and be no more than 7 pages from Section 2 onwards (excluding Resumes or Biographies). 5. Information provided in italics in each section of the application, is given as a guide only. 6. The review process is as follows    1. The AUSiMED Medical Science Review Board will be responsible for reviewing and recommending applications for funding by potential donors. Peer review will be considered as directed by this Committee.  The Medical Science Review Board consists of clinical, medical and scientific research specialists.  *Note regarding Conflict of Interest*: any member of the Medical Science Review Board that has a conflict of interest with a particular application will not be present during discussion of that application.    2. As part of the review process, applicants might be asked to provide additional information in writing, or to meet with the AUSiMED Medical Science Review Board in person or by teleconference.    3. Final approval for funding will be made by the AUSiMED Board 7. The support of AUSiMED is to be acknowledged in all papers, abstracts and presentations that result from this project. 8. If successful, the Applicants give permission for AUSiMED to publish the title of the Project, the names of the Applicants, a non-confidential summary describing the work to be completed, and at the completion of the Project, to publicise non-confidential outcomes. 9. Reports:   Financial and Progress Reports will be required each six (6) months during the Project. Other regular phone meetings will be arranged as required.  A Final Report will be required within 1 month following the completion of the project. Reporting templates will be provided as part of the award of funds.  Applicants may also be requested to lead educational seminars discussing the work that is being funded as well as outcomes of the completed project. |
| Lodging Applications |
| Please apply by submitting **a signed pdf copy by email**. You will receive acknowledgement of receipt.  e | **info@ausimed.org** |

|  |  |
| --- | --- |
| 1. Project Title, Contact Information | |
| **Project Title  (approx 10 words)**  *If project is successful, this title will be used publicly* |  |
| **Key Senior Contacts – Australia**  *Add more names as needed* | **Title:**  **Name:**  Organisation:  Position:  Phone/email:  Address: |
| **Key Senior Contacts – Israel**  *Add more names as needed* | **Title:**  **Name:**  Organisation:  Position:  Phone/email:  Address: |
| **Date of Application** |  |
| **Is this a new or ongoing project? Provide details of any related projects that are currently funded.** |  |
| **Amount of total funding requested from AUSiMED** |  |
| **AUSiMED Project Number** *[AUSiMED Use Only]* | **AIM #:** |

|  |
| --- |
| 2. Project Objectives, Description and Outcomes |
| **2.1 Project Description – Summary (500 words max)**  *Short summary of the project in lay terms including: the problem you are trying to solve, the likely clinical outcomes, and the reasons* w*hy this project is clinically relevant/important or necessary?* |
| * 1. **Specific Project Details**   *Describe objectives of the project.*  *How the project will be carried out?*  *Project duration and the activities to be undertaken by each team.*  *What is innovative about this project?*  *What are the risks in the project that might prevent the objectives being reached?* |
| **2.3 Anticipated Outcomes**  *What direct benefits will the project yield if it is successful?*  *Who will benefit (eg. patients, medical professionals, others)? Would there be wider benefits in addition to the direct benefits? What is needed to "translate" the outcomes from this project to clinical practice?*  *Describe where you will seek funds from to take this project to the next stage (after the completion of this project).* |
| **2.4 IP Ownership Arrangements**  *Has any IP been protected? (include copies of front page of patent applications if available). What are the arrangements for ownership of IP? Include copies of letters of intent if available. Are any licenses required to conduct the project? If yes, include copies of page 1 and signature pages of relevant license agreements.* |
| **2.5 Involvement of Commercialisation/Tech Transfer Companies**  *If university/institution technology transfer & commercialisation companies are involved, please provide names and contact details.* |
| **2.6 Project Stages and Milestones**  *Provide milestones that will be used to measure progress through to the end of the project.*   |  |  |  |  | | --- | --- | --- | --- | | Stages | Milestones: | Start & end dates | Funding needed | | Stage 1: | Milestone 1: |  |  | | Stage 2: | Milestone 2: |  |  | | Stage 3: | Milestone 3 |  |  | |
| **2.7 Importance of Collaboration.**  *Why is collaboration between Israel and Australia important to this project?* *How does this project combine ideas and skills from both the Australian and Israeli research teams? What are the likely spill-over benefits (eg knowledge transfer/diffusion, new skills, ongoing and/or new collaborations between the teams, license agreements)?* |

|  |
| --- |
| 3. Project Leadership and Key Personnel |
| **3.1 Project Leadership**  *Who is providing the intellectual and research direction for the project; who is responsible for ensuring the anticipated outcomes are achieved?* |
| **3.2 Relevant Experience**  *Include research and development; international collaborations; clinical & social outcomes etc. Attach brief Resumes or short biographies of the key people and details of their H rating score for publications if they have one.* |
| **3.3 Other Team Members not listed in Section 1** |
| **3.4 Time Commitment by the Project Team**  *Hours per month and % of each team member’s workload* |

|  |
| --- |
| 4. Project, Resources & AUSiMED Funding Request |
| **4.1 Resources required for the Project**  *Will the project use external infrastructure or equipment? If yes, please describe the infrastructure/equipment? Could any external infrastructure or equipment impact the timeline of the project?*  *If the project if currently in existence, how is this funding being provided now? Indicate if any funding is being received for this project, from Government grants (Australia & Israel) and other sources.* |
| **4.2 AUSiMED Funding Support – Indicative Budget –** *Please attach indicative budget including: how requested funds will be spent in each country, in-kind contributions, and funding that this project has received or will receive from other sources.* |

|  |
| --- |
| 6. Ethics Approvals |
| Does this project involve experiments on human subjects?  YES  NO  Is Ethics approval required from all institutions involved in the collaboration?  YES  NO Comment:  If YES, is Human Research Ethics Committee approval attached to this application from the relevant institution/s?  YES  NO  If NO, please comment.  If successful, funding for a project will not be released until Ethics Approval has been received and a copy of the approval letter has been received by the AUSiMED Committee. |

|  |  |
| --- | --- |
| 7. Certification by Applicants | |
| We certify that all the information given in this application is correct, and that the Project complies with all applicable local laws. We will accept the decision of the AUSiMED Scientific Review Committee and the AUSiMED Board as final. | |
| Signature of Project Leader – Israel | Date |
| Signature of Project Leader – Australia | Date |